2200 Sand Hill Road
9 articles with 5AM Ventures
Research platform enables biotech startups to outsource everything but the genius
In October, 5AM Ventures announced plans to raise $350 million for its sixth fund and it seems that the company has hit its mark. The money in that fund will be used to support the formation and development of new biotech companies.
Ribometrix closed on a Series A financing worth $30 million. The round was led by M Ventures, with participation of new investors Amgen Ventures, Pappas Capital and Illumina Ventures.
Cabaletta Bio launched out of the University of Pennsylvania with an exclusive license deal and two multi-year sponsored research agreements. The fledgling biotech company will work on engineered T cell products for B cell-mediated autoimmune disease.
New Haven, Connecticut-based Arvinas, only a few months since raising $55 million in a Series C financing, filed for an initial public offering (IPO). The company hopes to raise $100 million.
Akouos, based in Boston, announced a Series A financing worth $50 million. The round was led by seed investors 5AM Ventures and New Enterprise Associates (NEA).